Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):105-114. doi: 10.1007/s00259-019-04506-1. Epub 2019 Sep 6.

PMID:
31492992
2.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
3.

Uptake of Radium-223 Dichloride and Early [18F]NaF PET Response Are Driven by Baseline [18F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients.

Letellier A, Johnson AC, Kit NH, Savigny JF, Batalla A, Parienti JJ, Aide N.

Mol Imaging Biol. 2018 Jun;20(3):482-491. doi: 10.1007/s11307-017-1132-4.

PMID:
29027074
4.

18F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.

Selnæs KM, Krüger-Stokke B, Elschot M, Willoch F, Størkersen Ø, Sandsmark E, Moestue SA, Tessem MB, Halvorsen D, Kjøbli E, Angelsen A, Langørgen S, Bertilsson H, Bathen TF.

Eur Radiol. 2018 Aug;28(8):3151-3159. doi: 10.1007/s00330-017-5213-1. Epub 2018 Jan 2.

PMID:
29294158
5.

The Effect of Including Bone in Dixon-Based Attenuation Correction for 18F-Fluciclovine PET/MRI of Prostate Cancer.

Elschot M, Selnæs KM, Johansen H, Krüger-Stokke B, Bertilsson H, Bathen TF.

J Nucl Med. 2018 Dec;59(12):1913-1917. doi: 10.2967/jnumed.118.208868. Epub 2018 May 4.

6.

[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.

Ono M, Oka S, Okudaira H, Nakanishi T, Mizokami A, Kobayashi M, Schuster DM, Goodman MM, Shirakami Y, Kawai K.

Nucl Med Biol. 2015 Nov;42(11):887-92. doi: 10.1016/j.nucmedbio.2015.07.005. Epub 2015 Jul 15.

PMID:
26278491
7.

Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.

Chau A, Gardiner P, Colletti PM, Jadvar H.

Clin Nucl Med. 2018 Jul;43(7):e226-e231. doi: 10.1097/RLU.0000000000002130.

8.

Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.

Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C.

J Nucl Med. 2016 Sep;57(9):1350-6. doi: 10.2967/jnumed.115.170456. Epub 2016 Mar 3.

9.

A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.

Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H.

Clin Nucl Med. 2019 Oct;44(10):e566-e573. doi: 10.1097/RLU.0000000000002703.

PMID:
31283605
10.

Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Odewole OA, Tade FI, Nieh PT, Savir-Baruch B, Jani AB, Master VA, Rossi PJ, Halkar RK, Osunkoya AO, Akin-Akintayo O, Zhang C, Chen Z, Goodman MM, Schuster DM.

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1773-83. doi: 10.1007/s00259-016-3383-8. Epub 2016 Apr 18.

11.

18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J.

Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613.

PMID:
31375469
12.

Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.

Tade FI, Cohen MA, Styblo TM, Odewole OA, Holbrook AI, Newell MS, Savir-Baruch B, Li X, Goodman MM, Nye JA, Schuster DM.

J Nucl Med. 2016 Sep;57(9):1357-63. doi: 10.2967/jnumed.115.171389. Epub 2016 Apr 7.

13.

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Cook GJR.

Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):16-17. doi: 10.1007/s00259-019-04540-z. Epub 2019 Oct 17. No abstract available.

PMID:
31624865
14.

Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients.

Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, Guimaraes A, Vangel MG, Mahmood U, Soricelli A, Salvatore M.

Br J Cancer. 2015 Apr 28;112(9):1452-60. doi: 10.1038/bjc.2015.112. Epub 2015 Apr 14.

15.

A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.

Elschot M, Selnæs KM, Sandsmark E, Krüger-Stokke B, Størkersen Ø, Tessem MB, Moestue SA, Bertilsson H, Bathen TF.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):695-703. doi: 10.1007/s00259-016-3562-7. Epub 2016 Nov 5.

PMID:
27817158
16.

Prospective evaluation of fluciclovine (18F) PET-CT and MRI in detection of recurrent prostate cancer in non-prostatectomy patients.

Akin-Akintayo O, Tade F, Mittal P, Moreno C, Nieh PT, Rossi P, Patil D, Halkar R, Fei B, Master V, Jani AB, Kitajima H, Osunkoya AO, Ormenisan-Gherasim C, Goodman MM, Schuster DM.

Eur J Radiol. 2018 May;102:1-8. doi: 10.1016/j.ejrad.2018.02.006. Epub 2018 Feb 24.

17.

Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer.

Saarinen I, Jambor I, Kim M, Kuisma A, Kemppainen J, Merisaari H, Eskola O, Koskenniemi AR, Perez IM, Boström P, Taimen P, Minn H.

EJNMMI Res. 2019 May 31;9(1):50. doi: 10.1186/s13550-019-0518-5.

18.

Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F-Fluciclovine-PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases.

Oka S, Kanagawa M, Doi Y, Schuster DM, Goodman MM, Yoshimura H.

Int J Mol Sci. 2017 Apr 29;18(5). pii: E934. doi: 10.3390/ijms18050934.

19.

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.

Nanni C, Schiavina R, Brunocilla E, Boschi S, Borghesi M, Zanoni L, Pettinato C, Martorana G, Fanti S.

Clin Nucl Med. 2015 Aug;40(8):e386-91. doi: 10.1097/RLU.0000000000000849.

PMID:
26053708
20.

Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.

Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1873-1883. doi: 10.1007/s00259-018-4048-6. Epub 2018 May 16.

PMID:
29766246

Supplemental Content

Support Center